Evidence map›Paper›PMID 26766742›Full record

SynthesisBritish journal of cancer2016

CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk.

Xabier Garcia-Albeniz, Anja Rudolph, Carolyn Hutter, Emily White, Yi Lin, Stephanie A Rosse, Jane C Figueiredo, Tabitha A Harrison, Shuo Jiao, Hermann Brenner and 46 more

Registry-linked trialOpen access · hybridAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Genome-wide interaction analysis of folate for colorectal cancer risk.The American journal of clinical nutrition · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Cohort Profile: The Colon Cancer Family Registry Cohort (CCFRC).International journal of epidemiology · 2018
    Article
  14. Review
  15. Radical Cystectomy is the best choice for most patients with muscle-invasive bladder cancer? | Opinion: No.International braz j urol : official journal of the Brazilian Society of Urology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors at 20 institutions in 5 countries.

Xabier Garcia-AlbenizDepartment of Epidemiology, Harvard T.H., Chan School of Public Health, Boston, MA 02115, USA.
Anja RudolphDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Carolyn HutterDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Emily WhitePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Yi LinPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Stephanie A RossePublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Jane C FigueiredoDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Tabitha A HarrisonPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Shuo JiaoPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Hermann BrennerDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Graham CaseyDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Thomas J HudsonOntario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
Mark ThornquistPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Loic Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
John PotterPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Martha L SlatteryDepartment of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.
Brent ZankeClinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada.
John A BaronDivision of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7080, USA.
Bette J CaanDivision of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94612, USA.
Stephen J ChanockDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4608, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4608, USA.
Deanna StellingPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Charles S FuchsDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Michael HoffmeisterDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Katja ButterbachDivision of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Mengmeng DuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
W James GaudermanKeck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK.
Mathieu LemireOntario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
Shuji OginoDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA.
Jennifer LinChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Richard B HayesDivision of Epidemiology, Department of Population Health, New York University School of Medicine, New York, NY 10016, USA.
Robert W HaileDepartment of Medicine, Stanford University, Stanford, CA 94304, USA.
Robert E SchoenDepartment of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213-2582, USA.
Greg S WarnickPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Mark A JenkinsMelbourne School of Population Health, The University of Melbourne, Melbourne, VIC 3010, Australia.
Stephen N ThibodeauDepartments of Laboratory Medicine, Pathology and Laboratory Genetics, Mayo Clinic, Scottsdale, AZ 85259, USA.
Fredrick R SchumacherDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
Noralane M LindorDepartment of Health Sciences Research, Mayo Clinic, Scottsdale, AZ 85259, USA.
Laurence N KolonelEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
John L HopperMelbourne School of Population Health, The University of Melbourne, Melbourne, VIC 3010, Australia.
Jian GongPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Daniela SeminaraDivision of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Bethann M PflugeisenDepartment of Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Cornelia M UlrichPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Conghui QuDepartment of Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
David DugganTranslational Genomics Research Institute (Tgen), Phoenix, AZ 85004, USA.
Michelle CotterchioPrevention and Cancer Control, Cancer Care Ontario, Toronto, ON M5G 2L7, Canada.
Peter T CampbellEpidemiology Research Program, American Cancer Society, Atlanta, GA 30303, USA.
Christopher S CarlsonPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Polly A NewcombPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Edward GiovannucciDepartment of Epidemiology, Harvard T.H., Chan School of Public Health, Boston, MA 02115, USA.
Li HsuPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Andrew T ChanChanning Division of Network Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ulrike PetersPublic Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Memorial Sloan Kettering Cancer Center · USFred Hutch Cancer Center · USBrigham and Women's Hospital · USHeidelberg University · DENational Institutes of Health · USUniversity of Southern California · USMayo Clinic in Arizona · USOntario Institute for Cancer Research · CAThe University of Melbourne · AUAmerican Cancer Society · USCancer Care Ontario · CADana-Farber Cancer Institute · USHarvard University · USImperial College London · GBKaiser Permanente · USNational Center for Tumor Diseases · DENew York University · USOttawa Hospital · CAStanford University · USTranslational Genomics Research Institute · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
JH/CIDR Genotyping for Genome-Wide Association StudiesU01HG004438 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 2007 to 2011
$24.2M
GENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2M
Multiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2M
Molecular pathological epidemiology of colorectal cancerU01CA137088 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERS, ULRIKE · 2009 to 2018
$21.8M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
VALIDATION OF A DIET HISTORY METHOD FOR EPIDEMIOLOGIC STUDIES OF CANCERP01CA033619 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1985 to 2010
$18.5M
SEATTLE FAMILIAL COLORECTAL CANCER REGISTRYU01CA074794 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWCOMB, POLLY A · 1997 to 2007
$14.1M
CIHRIntramural NIH HHS Z01 CP010200NCI NIH HHS CA-95-011NCI NIH HHS K05 CA154337NCI NIH HHS P01 CA033619NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA 127003NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA048998NCI NIH HHS R01 CA059045NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA076366NCI NIH HHS R01 CA137178NCI NIH HHS R01 CA48998NCI NIH HHS R01 CA63464NCI NIH HHS R25 CA094880NCI NIH HHS R35 CA197735NCI NIH HHS R37 CA054281NCI NIH HHS R37 CA54281NCI NIH HHS U01 CA074783NCI NIH HHS U01 CA074794NCI NIH HHS U01 CA097735NCI NIH HHS U01 CA122839NCI NIH HHS U01 CA137088NCI NIH HHS U01 CA164930NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA206110NCI NIH HHS UM1 CA167551NHGRI NIH HHS U01 HG 004438NHGRI NIH HHS U01 HG004438NHGRI NIH HHS U01 HG004446NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100003INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100046CNHLBI NIH HHS HL115606NHLBI NIH HHS R21 HL115606NIA NIH HHS HHSN271201100004CNIDDK NIH HHS K24 DK098311NIDDK NIH HHS K24DK098311NIH HHS S10 OD020069WHI NIH HHS HHSN268201100001CWHI NIH HHS HHSN268201100002CWHI NIH HHS HHSN268201100003CWHI NIH HHS HHSN268201100004C
6 · The paper itself

Abstract

backgroundMenopausal hormone therapy (MHT) use has been consistently associated with a decreased risk of colorectal cancer (CRC) in women. Our aim was to use a genome-wide gene-environment interaction analysis to identify genetic modifiers of CRC risk associated with use of MHT.

methodsWe included 10 835 postmenopausal women (5419 cases and 5416 controls) from 10 studies. We evaluated use of any MHT, oestrogen-only (E-only) and combined oestrogen-progestogen (E+P) hormone preparations. To test for multiplicative interactions, we applied the empirical Bayes (EB) test as well as the Wald test in conventional case-control logistic regression as primary tests. The Cocktail test was used as secondary test.

resultsThe EB test identified a significant interaction between rs964293 at 20q13.2/CYP24A1 and E+P (interaction OR (95% CIs)=0.61 (0.52-0.72), P=4.8 × 10(-9)). The secondary analysis also identified this interaction (Cocktail test OR=0.64 (0.52-0.78), P=1.2 × 10(-5) (alpha threshold=3.1 × 10(-4)). The ORs for association between E+P and CRC risk by rs964293 genotype were as follows: C/C, 0.96 (0.61-1.50); A/C, 0.61 (0.39-0.95) and A/A, 0.40 (0.22-0.73), respectively.

conclusionsOur results indicate that rs964293 modifies the association between E+P and CRC risk. The variant is located near CYP24A1, which encodes an enzyme involved in vitamin D metabolism. This novel finding offers additional insight into downstream pathways of CRC etiopathogenesis.

Indexed as

AdenocarcinomaAgedBayes TheoremCase-Control StudiesColorectal NeoplasmsDrug Therapy, CombinationEstrogen Replacement TherapyEstrogensFemaleGene-Environment InteractionGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansLogistic ModelsMiddle AgedCYP24A1 protein, humanEstrogensProgestinsVitamin D3 24-Hydroxylase

Identifiers

PMID26766742
PMCPMC4815813
OpenAlexW2396983630

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.